U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Substance Use Tools & Resources   

Read the Guide

This collection of tools and resources is for providers, staff, and patients who offer or use services to address substance use, and other interested stakeholders. This collection was originally established following an environmental scan on implementing medication-assisted treatment (MAT) for opioid use disorder (OUD) in rural primary care. (See PDFs of Volume 1 [PDF 0.69 MB] and Volume 2 [PDF 1.28 MB] of that scan). Items have been continuously added to this collection since then, and the collection has expanded to cover substance use more broadly, rather than just MAT for OUD.

Displaying 11 - 20 of 117

Medications to Treat Opioid Use Disorder

This fact sheet includes basic descriptions of medications for opioid use disorders (MOUD) including naltrexone, buprenorphine, and methadone. It also addresses how MOUD can help those struggling with opioid use disorder, misunderstandings about MOUD, and additional considerations.
Format
Fact Sheet/Brochure
Audience
Patients
Families
Medical Providers
Other Team Members
Communities
Schools
Source
Partnership to End Addiction
Year
Resource Type
Web Page

Opioid-Overdose Reduction Continuum of Care Approach (ORCCA): A Policymakers Guide to Implementing Evidence-Based Strategies that Address Opioid Overdose

This publication is intended to aid policymakers, communities, and key stakeholders in developing comprehensive, multi-system strategies that address the opioid crisis.
Format
Guide
Audience
Policymakers and Payers
Communities
Source
National Institutes of Health (NIH) HEAL Initiative
Year
Resource Type
PDF
File Size
1.3 MB

Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl

These guidelines provide practical clinical practice-based guidance, based on available research combined with emerging clinical experience, on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.

Format
Guide
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Provider Clinical Support System (PCSS)
Year
Resource Type
PDF
File Size
1646 KB

Requirements for training for Medication Assisted Treatment as part of the MATE Act

This letter announces details on the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.
Format
Fact Sheet/Brochure
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Drug Enforcement Administration (DEA)
Year
Resource Type
PDF
File Size
245 KB

SAMHSA Training Requirements (MATE Act) Resources

This SAMHSA page includes information on 2023 training requirements that eliminated the DATA waiver that was previously needed to prescribe buprenorphine and expanded the number of DEA-registered practitioners able to treat people with opioid use disorder.
Format
Web Page
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Substance Abuse and Mental Health Services Administration (SAMHSA)
Year
Resource Type
Web Page

The Role of Low-Threshold Treatment for Patients with Opioid Use Dusirder (OUD) in Primary Care

This Topic Brief provides an overview of what constitutes low-threshold treatment for patients with OUD, the state of the evidence and patient perspectives on low-threshold OUD treatment, and key steps and strategies for providing low-threshold treatment for patients with OUD in primary care settings.
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Agency of Healthcare Quality and Research (AHRQ) Integration Academy
Year
Resource Type
Web Page

Updated DEA Registration Certificate after Removal of X-Waiver

This guidance document provides information regarding issuance of updated DEA registration certificates to reflect Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).
Format
Fact Sheet/Brochure
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Drug Enforcement Administration (DEA)
Year
Resource Type
PDF
File Size
92.4 KB

Waiver Elimination (MAT Act)

This web page provides frequently asked questions regarding the 2023 Consolidated Appropriations Act, which eliminates the X-waiver (DATA-Waiver) and increases accessibility of medication-assisted treatment (MAT).
Format
Web Page
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Substance Abuse and Mental Health Services Administration (SAMHSA)
Year
Resource Type
Web Page

A Practical Research Agenda for Treatment Development for Stimulant Use Disorder - Meeting Summary: May 2022

This document summarizes a discussion from a workshop where experts examined the evidence for candidate endpoints and study design strategies for clinical trials of stimulant use disorder treatments.
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Reagan-Udall Foundation for the FDA (Food and Drug Administration)
Year
Resource Type
PDF
File Size
674 KB